Editorial Board Members | Published 30th September 2021
Introductions to new Editorial Board Members
Dr. Graham Steele
Graham is an experienced microbiologist with a broad background in consultancy, teaching and research.
He was Head of the Department of Biomedical Sciences at the University of Bedfordshire until 2002, when he left to develop his role as a Consultant Microbiologist to the pharmaceutical and medical device manufacturing industries in the areas of sterilization and contamination control.
From 2002-08 he worked for Albert Browne (Steris) Ltd, where he led a programme on the improvement of reproducibility in biological indicators.
From 1992-2014 he also held the role of Consultant Microbiologist at Guardian Surgical (Berendsen) Ltd. where he was responsible for the development of the microbiological monitoring programme and overseeing ongoing environmental monitoring. He is currently engaged as Consultant Microbiologist to Franz Ziel GmbH in Germany.
He has nearly 40 years’ experience in higher education, lecturing on a wide range of subjects in the field of microbiology. His principal research interests have focussed on microbial resistance to stress and the detection of microorganisms in materials ranging from medical products to foodstuffs.
He has served on the Management Committee of the PHSS since October 2008.
He holds a BSc. in Plant and Soil Microbiology from the University of Liverpool and a PhD. in Mycology from the University of London.
Dr Rossen Donev
Rossen Donev received his PhD degree in 1999. He did postdoctoral training at the Imperial Cancer Research Fund, UK and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principal Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 70 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. Since 2010 he serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology (Elsevier) and on editorial board of Frontiers in Neurogenomics as Associate Editor. His research interests include signalling pathways involved in neuropsychiatric disorders and tumour escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutic formulations for non-systemic applications.